



## Prospective Studies – in mUM

1. **Zager J. S., Orloff M. M., Ferrucci P. F., et al.**  
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study. *Ann Surg Oncol* 31, 5340–5351 (2024); doi.org/10.1245/s10434-024-15293-x
2. **Meijer T. S., Burgmans M. C., de Leede E. M., et al.**  
Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study. *Ann Surg Oncol* (2021) 28:1130–1141; doi.org/10.1245/s10434-020-08741-x.
3. **Meijer T. S., Burgmans M. C., Fiocco M., et al.**  
Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems' Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial. *Cardiovasc Intervent Radiol* (2019) 42:841–852; doi.org/10.1007/s00270-019-02177-x
4. **Tong T. M. L., Burgmans M. C., Speetjens F. M., et al.**  
Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial. *Cardiovasc Intervent Radiol*; doi.org/10.1007/s00270-022-03338-1.

## Quality of Life Data – in mUM

5. **Vigneswarana G., Malalasekera W., Smith V., et al.**  
Quality of life after melphalan percutaneous hepatic perfusion for patients with metastatic Uveal Melanoma. *Melanoma Res*; DOI: 10.1097/CMR.0000000000000947.
6. **Tong T. M. L., Fiocco M., van Duijn-de Vreugd J. J., et al.**  
Quality of Life Analysis of Patients Treated with Percutaneous Hepatic Perfusion for Uveal Melanoma Liver Metastases. *Cardiovasc Intervent Radiol*; doi.org/10.1007/s00270-024-03713-0


## Retrospective Studies – comparative in mUM

7. **Kolb M., Forschner A., Artzner C., et al.**  
Selective Internal Radiotherapy (SIRT) and Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) for Metastasized Uveal Melanoma: A Retrospective Comparative Study. *Cancers* 2023, 15(20), 4942; doi.org/10.3390/cancers15204942.

## Retrospective Studies – safety and efficacy (in mUM)

8. **Tong T. M. L., Samim M., Kapiteijn E., et al.**  
Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis. *Cardiovasc Intervent Radiol* (2022) 45:1304–1313
9. **Artzner C., Mossakowski O., Hefferman G., et al.**  
Chemosaturation with percutaneous hepatic perfusion of melphalan for liver dominant metastatic uveal melanoma: a single center experience. *Cancer Imaging* (2019) 19:31; doi.org/10.1186/s40644-019-0218-4.

*Continued Overleaf.*



## Retrospective Studies – safety and efficacy (in mUM) *continued*

- 10.** Brüning R., Tiede M., Schneider M., et al.  
 Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalan—Long-Term Overall Survival Negatively Correlates with Tumor Burden. *Radiology Research and Practice*, Volume 2020, Article ID 5672048, 7 pages; doi.org/10.1155/2020/5672048.
- 11.** Dewald C. L. A., Warnke M., Brüning R., et al.  
 Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience. *Cancers* 2022, 14(1), 118; doi.org/10.3390/cancers14010118.
- 12.** Modi S., Gibson T., Vigneswaran G., et al.  
 Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma. *Melanoma Research* 32(2):p 103-111, April 2022; DOI: 10.1097/CMR.0000000000000806.
- 13.** Dewald C. L. A., Becker L. S., Maschke S. K., et al.  
 Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery. *Clinical & Experimental Metastasis* (2020) 37:683–692; doi.org/10.1007/s10585-020-10057-9.

## Retrospective Studies – mUM and other indication

- 14.** Vogel A., Ochsenreither S., Zager J. S., et al.  
 Chemosaturation for primary and secondary liver malignancies: A comprehensive update of current evidence. *Cancer Treatment Reviews*; doi.org/10.1016/j.ctrv.2022.102501.
- 15.** Veelken R., Maiwald B., Strocka S., et al.  
 Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers. *Cardiovasc Intervent Radiol* (2022) 45:218–222; doi.org/10.1007/s00270-021-02983-2.
- 16.** Schönfeld L., Hinrichs J. B., Marquardt S., et al.  
 Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma. *Journal of Cancer Research and Clinical Oncology* (2020) 146:3003–3012; doi.org/10.1007/s00432-020-03289-5.
- 17.** Marquardt S., Kirstein M. M., Brüning R., et al.  
 Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. *European Radiology*; doi.org/10.1007/s00330-018-5729-z.